

Suppression of Macrophage Migration Inhibitory Factor in Children with Severe Malarial Anemia: Role of Monocyte-acquired Hemozoin

Gordon A. Awandare^{1,2,3}, Yamo Ouma², Collins Ouma², Tom Were², Richard Otieno²,
Christopher C. Keller⁴, Gregory C. Davenport¹, James B. Hittner⁵, John Vulule⁶
Robert Ferrell⁷, John M. Ong'echa², Douglas J. Perkins^{1,2}

¹Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.

²University of Pittsburgh/KEMRI Laboratories of Parasitic and Viral Diseases, Kisumu, Kenya.

³Department of Biochemistry, University of Ghana, Legon, Accra, Ghana.

⁴Lake Erie College of Osteopathic Medicine, Erie, PA

⁵Department of Psychology, College of Charleston, Charleston, SC.

⁶Centre for Vector Biology and Control Research, Kenya Medical Research Institute, Kisumu, Kenya.

⁷Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA.

Running title: Hemozoin-induced MIF suppression in SMA

Word counts:

Abstract: 250

Text: 4531

FOOTNOTE PAGE

A portion of this work was presented at the fourth Multilateral Initiative on Malaria (MIM) Pan-African malaria conference held in Yaoundé, Cameroon (13th-18th November 2005). The study was approved by the Ethics Committees of the Kenya Medical Research Institute (KEMRI), Kenyan Ministry of Health and the University of Pittsburgh Institutional Review Board, and informed consent was obtained from all participants or the parents/legal guardians of all participating children.

There is no conflict of interest for any of the authors of the manuscript due to either commercial or other affiliations.

The study was funded from a National Institutes of Health (NIH) Grant 1 R01 (DJP) and a Fogarty International Center (FIC) Training Grant 1 D43 (DJP).

Please address any correspondence to:

Douglas Jay Perkins, PhD

University of Pittsburgh, Graduate School of Public Health,

Department of Infectious Diseases & Microbiology,

130 DeSoto Street, 603 Parran Hall,

Pittsburgh, PA, 15261

Phone (412)-624-5894

Fax (412)-624-5364

E-mail: djp@pitt.edu

SUMMARY

Severe malarial anemia (SMA), caused by *Plasmodium falciparum* infections, is one of the leading causes of childhood mortality in sub-Saharan Africa. Although the molecular determinants of SMA are largely undefined, dysregulation in host-derived inflammatory mediators influences disease severity. Macrophage migration inhibitory factor (MIF) is an important regulator of innate inflammatory responses that has recently been shown to suppress erythropoiesis and promote pathogenesis of SMA in murine models. To examine the role of MIF in the development of childhood SMA, peripheral blood MIF production was examined in Kenyan children (aged <3 years, n=357) with *P. falciparum* malarial anemia. All children in the study were free from bacteremia and HIV-1. Since deposition of malarial pigment (hemozoin) contributes to suppression of erythropoiesis, the relationship between MIF concentrations and monocytic acquisition of Hz was also examined *in vivo* and *in vitro*. Circulating MIF concentrations declined with increasing severity of anemia and significantly correlated with peripheral blood leukocyte MIF transcripts. **However, MIF concentrations in peripheral blood were not significantly associated with reticulocyte production.** Multivariate regression analyses, controlling for age, gender and parasitemia, further revealed that elevated levels of pigment-containing monocytes (PCM) was associated with SMA and decreased MIF production. In addition, PCM levels were a better predictor of hemoglobin and MIF concentrations than parasite density. Additional experiments in malaria-naïve individuals demonstrated that hemozoin caused both increased and decreased MIF production in cultured peripheral blood mononuclear cells (PBMC) in a donor-specific manner, independent of apoptosis. However, PBMC MIF production in children with acute malaria progressively declined with increasing anemia severity. Results presented here demonstrate that acquisition of hemozoin by monocytes is associated with suppression of peripheral blood MIF production and enhanced severity of anemia in childhood malaria.

Key words: *Plasmodium falciparum*, malaria, anemia, MIF, malarial pigment (hemozoin)

INTRODUCTION

Annually, there are 350-500 million clinical cases of malaria that result in over one million deaths (68). The majority of malaria-related mortality are due to infections with *Plasmodium falciparum* and occur in immune-naïve infants and young children in sub-Saharan Africa, accounting for 18% of all deaths before five years of age (68). Severe malarial anemia (SMA) accounts for the greatest proportion of malaria related morbidity and mortality worldwide (13). In holoendemic *P. falciparum* transmission areas, SMA is the commonest clinical presentation of severe malaria in children less than three years of age, with cerebral malaria (CM) occurring only in rare cases (44, 51).

Markedly reduced hemoglobin (Hb) concentrations in children with SMA result from overlapping, but distinct processes including direct and indirect destruction of parasitized red blood cells (pRBC), increased clearance of uninfected erythrocytes, and suppression of erythropoiesis (1, 65, 69). Recent studies in western Kenya illustrate that children with SMA (Hb<6.0g/dL) have lower peripheral parasite densities than parasitemic children without anemia (Hb ≥11.0 g/dL) (44, 51), suggesting that acute hemolysis of RBCs is not likely responsible for the low Hb levels observed in children with SMA in this holoendemic region. It is well-documented that children with SMA have a number of bone marrow abnormalities including dyserythropoiesis, ineffective erythropoiesis, and reduced proliferation of erythroid colonies (1, 64, 65, 69). These findings, along with studies showing that the reticulocyte response is reduced relative to the degree of anemia in children with malarial anemia, even in the presence of elevated levels of erythropoietin (14, 36, 49), suggest that suppression of erythropoiesis may play a central role in the development of SMA.

Although the molecular mechanisms that regulate suppression of erythropoiesis are only partially defined, over-production of pro-inflammatory mediators is thought to play a prominent role in conditioning the severity of childhood malarial anemia (25, 35, 38, 42, 52, 55). Recent investigations by our laboratory (7, 33, 50, 67) and others (41, 43) have focused on defining the

role of pro-inflammatory mediators such as macrophage migration inhibitory factor (MIF) in the immunopathogenesis of malarial anemia, since MIF plays a pivotal role in regulating the innate immune response to invading pathogens (17). MIF is a pleiotropic cytokine released by several cell types including, monocytes/macrophages (15), T cells (8, 26), and cells of the anterior pituitary gland (11). Although MIF has potent pro-inflammatory properties that protect against *Salmonella typhimurium* (34), *Leishmania major* (31, 58, 70) and *Trypanosoma cruzi* (57), elevated levels of circulating MIF are also associated with enhanced pathogenesis of bacterial sepsis (11, 12, 16), suggesting that increased MIF production can elicit both protective and pathogenic responses in different infectious diseases.

Previous investigations have observed elevated levels of MIF protein in blood vessel walls of Malawian children with cerebral malaria (23, 24), and intervillous blood mononuclear cells from women with placental malaria (20, 21). Studies in murine models of malaria show that elevated plasma MIF concentrations are associated with suppression of erythropoiesis and enhanced severity of anemia (41, 43). However, our recent investigations, which were the first to report circulating MIF levels in children with malaria, demonstrated that peripheral blood MIF concentrations and peripheral blood mononuclear cell (PBMC) MIF mRNA expression were reduced in Gabonese children with mild-to-moderate forms of malarial anemia and hyperparasitemia (7). In contrast, subsequent studies have shown that plasma MIF levels are elevated in Zambian children with malarial anemia (43).

Although the host-parasite interactions that mediate MIF production are largely undefined, studies from our laboratory (32, 33, 54), and others (5, 43, 56, 61) show that ingestion of malarial pigment, hemozoin (Hz) by phagocytic cells causes dysregulation in cytokine production. Hz is a coordinated aggregation polymer of heme generated by *Plasmodia* during digestion of host Hb (28). During a malaria infection, Hz is acquired by leukocytes through direct phagocytosis of pRBC and free Hz released upon pRBC rupture (60). Recent studies have demonstrated that Hz contributes to the pathogenesis of SMA by suppressing

erythropoiesis both directly and in synergy with pro-inflammatory cytokines such as TNF- α (18). In addition, acquisition of Hz by murine macrophages and human monocytes is associated with enhanced MIF production (41, 43).

To investigate the role of MIF in the immunopathogenesis of malarial anemia, peripheral blood MIF concentrations and leukocyte MIF transcript levels were measured in infants and young children residing in a holoendemic *P. falciparum* transmission area where severe anemia is the primary clinical manifestation of severe malaria. In addition, to examine host-parasite interactions that may be important for regulating MIF production, the relationship between circulating MIF levels and monocytic acquisition of Hz was determined. The direct effect of Hz on MIF production was also investigated in cultured PBMC from malaria-naïve individuals. *In vivo* and *in vitro* results presented here demonstrate that MIF is suppressed in children with SMA and that monocyte-acquired *p*Hz plays an important role in promoting SMA and decreasing MIF production.

STUDY PARTICIPANTS, MATERIALS, AND METHODS

Study site. Children (n=357, age 3-31 mos) were recruited at the pediatric ward of the Siaya District Hospital (SDH), Nyanza Province, western Kenya. In this region, malaria is holoendemic with entomological inoculation rates of up to 300 per annum (9). Approximately 1/3 of all pediatric admissions to SDH are due to SMA, which accounts for ~50% of all pediatric deaths at hospital (37). A detailed description of the study site and cohort is provided in our recent report (44, 51).

Study participants. A questionnaire and medical informatics system were used to recruit children at their first hospital contact for the treatment of malaria. After obtaining informed written consent from the parents/guardians of children presenting at SDH with the signs and symptoms of malaria, heel/finger-prick blood (<100 μ L) was used to determine parasitemia and Hb concentrations. Children with *P. falciparum* parasitemia (any density) were categorized according to the following criteria: uncomplicated malaria (UM, Hb \geq 11.0 g/dL, n=26); mild malarial anemia (MIMA, 8.0 \leq Hb<11.0 g/dL, n=75), moderate malarial anemia (MdMA, 6.0 \leq Hb<8.0 g/dL, n=98); and SMA (Hb<6.0 g/dL, n=119). Case definitions of anemia were based on previous studies in western Kenya examining >10,000 longitudinal Hb measurements in an age- and geographically-matched population (44). Healthy, aparasitemic children (AC, Hb \geq 11.0 g/dL, n=39) presenting at SDH for routine immunizations were recruited as controls. In addition, only those children that were afebrile for \geq 2 weeks were included in the AC group. None of the children in the current study had any signs/symptoms of CM. Since HIV-1 and bacteremia are common co-pathogens that influence anemia status in children with malaria (2, 10, 29, 53), and could influence MIF production, all study participants were screened for HIV-1 and/or bacteremia and those children found to have co-pathogens were excluded from all analyses. Pre- and post-test HIV counseling was provided to parents/guardians of all children

enrolled. The study was approved by the Ethics Committees of the Kenya Ministry of Health and the University of Pittsburgh Institutional Review Board.

Sample collection. Prior to administration of antimalarials and/or any other treatment interventions, venous blood (<3 mL: a volume determined to be safe based on size, weight, and anemia status) was collected, and plasma isolated according to our previous methods (44, 51). Leukocytes were obtained from the buffy coat by lysing RBC followed by storage in RNeasy[®] (Ambion) at -20°C until use.

Laboratory evaluation. Giemsa-stained blood smears were used to determine parasitemia and pigment-containing monocytes and neutrophils. The number of RBC infected with asexual *P. falciparum* parasites were determined per 300 leukocytes, and peripheral parasite density/ μ L of blood was calculated using the WBC count/ μ L obtained on a Coulter[®] A^cT diff2[™] (Beckman Coulter Corp.). A total of 30 monocytes and 100 neutrophils were examined per thin smear, and the number of pigment-containing monocytes (PCM) or pigment-containing neutrophils (PCN) was expressed as a percentage of the total number of monocytes and neutrophils, respectively (39, 48). The number of PCM/ μ L of blood was calculated by multiplying the percent of PCM by the absolute number of monocytes/ μ L obtained from the Coulter[®] A^cT diff2[™]. Reticulocyte counts (percent) were determined using new methylene-blue-stained slides, and the absolute reticulocyte number (ARN) was calculated by multiplying the reticulocyte percent/100 by total RBC counts. HIV-1 status was determined per our previously described HIV-1 serology and PCR methods (53), while bacteremia was determined using the Wampole[™] ISOLATOR[™] 1.5 mL microbial system (Inverness Medical).

Determination of plasma MIF and leukocyte MIF transcript levels. To avoid the possible influence of MIF released from lysis of erythrocytes (47) during blood clotting, circulating MIF levels were determined in plasma rather than serum samples. In addition, visibly hemolyzed samples were excluded from measurements. Plasma and culture supernatant MIF concentrations were determined by ELISA with a matched anti-MIF antibody pair (R&D systems). All samples were assayed at 1:5 and 1:10 dilutions in duplicate, and according to manufacturer's recommendations. The limit of detection was >31.25 pg/mL. For determination of MIF transcript levels, total RNA was extracted from leukocyte pellets using the guanidinium isothiocyanate (GITC) method as described previously (22). Fluorogenic primer/probe sets specific for MIF and the housekeeping gene, β -actin (assay IDs Hs00236988_g1 and 4326315E respectively, Applied Biosystems) were used for real time RT-PCR on an ABI Prism[®] 7700 sequence detection system (Applied Biosystems). MIF mRNA levels were normalized by expressing transcripts as fold-change relative to β -actin mRNA ($2^{-\Delta C_T}$, where ΔC_T =critical threshold cycle of MIF – critical threshold cycle for β -actin), as described previously (7).

PBMC cultures. Venous blood was obtained from healthy, malaria-naïve US donors (n=15) and children with acute malaria (n=94). PBMC were isolated using Ficoll-Hypaque according to previous methods (66). To ensure complete removal of RBC, PBMC were treated with RBC lysis buffer (BioWhittaker) for five minutes and then washed prior to culture. *P. falciparum*-derived Hz (*pfHz*) was isolated from laboratory-cultivated *P. falciparum* (PfD6) and synthetic Hz (*sHz*) was prepared from hemin chloride (Sigma) as described previously (32). Endotoxin levels in all *pfHz* and *sHz* preparations were determined to be <0.125 U/mL (i.e., <0.025 ng/mL; *Limulus ameobocyte* lysate test, BioWhittaker). PBMC were plated at 1×10^6 cells/mL in Dulbecco's modified Eagles medium (DMEM) containing HEPES buffer (25mM), penicillin (100 U/mL)/streptomycin (100 μ g/mL) and 10% heat inactivated human serum from a non-malarious

region. Experiments conducted in children with acute malaria were cultured in media alone, while PBMC from US donors were stimulated with media alone (unstimulated control), physiological concentrations of *p*fHz (10 µg/mL) (33), sHz (10 µg/mL), or lipopolysaccharide (LPS, 100 ng/mL; Alexis Corp.) and interferon (IFN)-γ (200 U/mL; Biosource).

Cell viability and apoptosis assays. Viability of cultured PBMC was determined using a methylthiazolotetrazolium (MTT)-based assay according to manufacturer's recommendations (Sigma). Cellular apoptosis was assessed by quantifying the concentrations of nucleosomes in cell lysates (early-stage apoptosis) and culture supernatants (late-stage apoptosis) using a cell death detection ELISA (Roche Diagnostics) according to manufacturer's recommendations, with nucleosome concentrations in treated cells expressed as a percentage relative to untreated cells (control).

Statistical analyses. Kruskal-Wallis tests were used to compare variables across three or more groups, and where significant differences were observed, Mann-Whitney U tests were conducted for pairwise comparisons. Statistical associations between variables were examined using Pearson's correlation tests, and multivariate linear and logistic regression analyses, controlling for age and gender. Prior to performing Pearson's correlational analyses, the distributional characteristics of all variables were examined for departures from normality using the Kolmogorov-Smirnov test. Those variables with significant skewness were transformed toward normality. *p*-values less than 0.05 were considered statistically significant for all analyses.

RESULTS

Clinical, parasitological, and hematological characteristics of study participants. To examine the role of MIF in the immunopathogenesis of malarial anemia, children (n=357) were stratified into clinical anemia categories. The clinical, parasitological, and hematological characteristics of the study participants upon admission are summarized in Table 1. Across-group comparisons showed significant differences in age ($p=0.005$) and axillary temperature ($p<0.001$). Children in the UM group were significantly older relative to all other groups ($p<0.01$ for all comparisons). Axillary temperature was elevated in all categories of children with acute malaria relative to the AC group ($p<0.001$ for all groups). Mean peripheral parasitemia ($p=0.117$), geometric mean parasitemia, and the proportions of children with HDP ($\geq 10,000$ parasites/ μL ; $p=0.656$) were not significantly different among children with acute malaria (Table 1). Since anemia severity was the basis for classification, Hb and RBC numbers decreased across the groups ($p<0.001$ for both comparisons). In contrast, the ARN increased with increasing severity of anemia ($p<0.001$). Taken together, these data illustrate that the severity of anemia in this holoendemic *P. falciparum* transmission region is not significantly associated with peripheral parasite density.

Circulating MIF levels progressively decline with increasing severity of malarial anemia.

Our previous investigations showed that peripheral blood MIF concentrations were suppressed in a small cohort of children with acute malaria (7). In contrast, additional studies (also limited by sample size) illustrated that plasma MIF concentrations were elevated in children with acute malaria (43). To more fully investigate the role of MIF in the immunopathogenesis of childhood malaria, children were stratified according to malarial anemia status and circulating MIF levels were examined in the following groups: UM ($n=23$), MIMA ($n=71$), MdMA ($n=94$) and SMA ($n=109$); and healthy, a parasitemic controls (AC, $n=39$). As shown in Figure 1A, MIF concentrations progressively declined in parasitemic children with increasing severity of anemia.

Children with SMA [median (interquartile range) 3422 (1566-4993) pg/mL] had lower plasma MIF levels than the AC [4383 (2807-6376) pg/mL, $p<0.05$], UM [5225 (3615-9071) pg/mL, $p<0.001$], and MIMA [4611 (3270-6665) pg/mL, $p<0.001$] groups (Figure 1A). In addition, there was a significant positive correlation between circulating MIF levels and Hb concentrations ($r=0.23$, $p<0.001$) and a significant inverse correlation between plasma MIF levels and parasitemia ($r=-0.16$, $p<0.05$) among children with malaria (Figures 1B and C). However, there was a non-significant correlation between circulating MIF concentrations and the absolute reticulocyte number ($r=0.10$, $p=0.10$, Figure 1D). Multiple regression analysis, controlling for age and gender, further revealed that MIF was a significant positive predictor of Hb concentration (standardized partial regression coefficient, β -weight=0.153, $p<0.005$) and a negative predictor of parasitemia (β -weight=-0.096, $p=0.067$). These results demonstrate that SMA is characterized by reduced peripheral blood MIF concentrations and that pRBC and/or a parasitic product(s) either directly or indirectly promote suppression of MIF concentrations.

Peripheral blood leukocyte MIF transcripts as a source of circulating MIF. Although MIF is produced by a number of different cell types (11, 15, 17), our recent investigations in Gabonese children with malaria demonstrated that suppression of plasma MIF concentrations was associated with decreased PBMC MIF transcripts (7). Based on the number of different experimental measures performed with limited blood sample volumes from children with malarial anemia, we opted to measure MIF transcripts in peripheral blood leukocytes (PBL) from a subset of children in which matched samples were available. These experiments revealed that MIF transcripts closely paralleled circulating MIF concentrations ($r=0.68$, $p=0.01$; Figure 2), suggesting that MIF gene expression in PBL may be an important source of circulating MIF levels.

MIF production from cultured PBMC progressively declines with increasing anemia severity. To further investigate MIF production in children with malarial anemia, PBMC MIF production was measured under baseline conditions in cultured cells isolated from children with varying degrees of malarial anemia and healthy controls: AC (n=24), UM (n=15), MIMA (n=37), MdMA (n=13), and SMA (n=5). MIF concentrations in culture supernatants were significantly increased in children with UM [median (interquartile range) 2218 (1418-3989) pg/mL] relative to the AC group [1034 (615-1902) pg/mL, $p < 0.005$, Figure 3) at 48 hrs. However, MIF production progressively declined with increasing anemia severity, with the SMA group [511 (264-2312) pg/mL] having lower culture supernatant MIF levels than the UM ($p < 0.05$), MIMA [1609 (940-2439) pg/mL, $p = 0.08$], and MdMA [842 (495-3737) pg/mL, $p = 0.43$] groups (Figure 3). MIF production did not significantly differ between the AC group and any of the malarial anemia groups (SMA, $p = 0.51$; MdMA, $p = 0.87$; and MIMA, $p = 0.06$). Taken together, these *in vitro* experiments demonstrate that reduced MIF production from PBMC contributes to decreased circulating MIF levels in children with malarial anemia. Furthermore, increased MIF production in children with a favorable clinical outcome (i.e., children with uncomplicated malaria) suggests that increased MIF production during childhood malarial anemia may provide a protective response against severe disease.

In vivo acquisition of *pf*Hz by monocytes is associated with enhanced SMA. Recent studies in individuals with malaria suggest that phagocytosis of *pf*Hz by monocytes and neutrophils is an important predictor of clinical severity (4, 18, 39, 48). Additional studies have demonstrated that sHz enhanced MIF production in mouse peritoneal macrophages and human mononuclear cells (43). To further examine the role of naturally acquired *pf*Hz in conditioning disease outcomes in children with malarial anemia, the relationship between intracellular malarial pigment and malaria disease severity was determined. Percentages of PCM ranged from 0-90% (mean=10%), while the percentages of PCN ranged from 0-9% (mean=0.3%), with

PCM present in 47% (144/306) and PCN present in 12% (37/306) of the study participants, respectively. Based on the higher abundance of PCM relative to PCN, we examined the impact of PCM on clinical outcomes. The proportion of pigment-containing monocytes (%PCM) and PCM/ μ L progressively increased across the acute malaria groups ($p < 0.001$ for both comparisons, see Table 1). In a multiple regression model controlling for age, gender, and parasitemia, PCM emerged as a strong predictor of Hb concentrations (β -weight=-0.434, $p < 0.001$).

To further investigate the role of PCM in conditioning the outcomes of acute malaria, children were stratified into three groups according to the distribution of PCM: *no PCM* (0% PCM), *low PCM* (PCM \leq 10%), and *high PCM* (PCM $>$ 10%). These analyses revealed that age was not significantly different across the groups ($p=0.645$). Moreover, although parasitemia increased with elevated PCM across the three groups ($p=0.034$, Table 2), parasitemia and the percentage of HDP did not significantly differ between the *high* and *low* PCM groups ($p=0.181$ and $p=0.086$, respectively, Table 2). Conversely, Hb concentrations decreased with increasing *p*fHz deposition ($p < 0.001$, across groups), with the *high PCM* group having the highest percentage of SMA cases (Table 2). Multiple logistic regression analyses controlling for age, gender, and parasitemia demonstrated that the risk of SMA was increased for the *low PCM* (OR=3.4; 95% CI, 1.8-6.6, $p < 0.0001$) and *high PCM* (OR=7.5; 95% CI, 4.1-14.0, $p < 0.0001$) groups relative to the *no PCM* group (Table 2). There was also an increased risk of SMA in the *high PCM* group compared to the *low PCM* group (OR=2.1; 95% CI, 1.1-4.3, $p < 0.05$). Thus, consistent with the demonstrated role of H₂ in suppression of erythropoiesis during malarial anemia (18), these results show that deposition of *p*fHz in circulating monocytes is associated with an increased prevalence of SMA.

In vivo acquisition of pfHz by monocytes is associated with suppression of MIF. Since PCM was strongly correlated with SMA, and MIF concentrations declined with increasing severity of anemia, the relationship between PCM and MIF was examined. The *high PCM* group had lower MIF levels [median (interquartile range), 3115 (1525-4879) pg/mL] than the *no PCM* [4417 (3112-6266) pg/mL; $p < 0.005$] and *low PCM* groups [4584 (1525-4879) pg/mL; $p < 0.05$, Figure 4A]. Furthermore, circulating MIF concentrations were significantly inversely correlated with PCM levels ($r = -0.23$, $p < 0.001$; Figure 4B). Multiple linear regression analyses controlling for age and gender further revealed that PCM (β -weight = -0.238 , $p < 0.001$) was a stronger predictor of MIF than parasitemia (β -weight = -0.087 , $p = 0.024$), suggesting that monocytic acquisition of p f Hz may contribute to suppression of MIF concentrations.

p f Hz and sHz decrease MIF production in cultured PBMC independent of apoptosis.

Since the *in vivo* results suggested that PCM may be an important factor for suppressing MIF production, the direct effect of malarial pigment on MIF production was examined in PBMC from healthy, malaria-naïve U.S donors. Cultures were stimulated with concentrations of p f Hz or sHz comparable to those in children with severe malaria (i.e., 10 μ g/mL) (33), and LPS and IFN- γ (L/I) as a positive control. Treatment of PBMC with p f Hz or sHz resulted in a significant increase in MIF production in 3/15 donors ($p < 0.05$ for all comparisons; Group 1, Figure 5A), while MIF production was significantly decreased in 11/15 donors ($p < 0.05$ for all comparisons; Group 2, Figure 5A). In addition, there was no significant change in MIF production in p f Hz- or sHz-stimulated PBMC from one donor (data not shown). Stimulation of PBMC with L/I increased MIF production in 9/15 donors ($p < 0.05$ for all comparisons, Figure 5A), while MIF production was not significantly altered in PBMC of 6/15 donors (data not shown).

Since p f Hz or sHz could alter MIF by influencing PBMC viability, cellular metabolism was investigated with the MTT assay. Relative to control conditions, stimulation with p f Hz or sHz

had no significant effect on cellular viability at 48 hrs ($p=0.601$ and $p=0.522$, respectively), while L/I reduced viability by 28% ($p<0.05$; Figure 5B). Examination of cellular apoptosis by measuring nucleosome release (DNA fragmentation) revealed that both early- and late-stage apoptosis were unaffected by sHz treatment ($p=0.247$, and $p=0.928$, respectively). However, stimulation with L/I increased both early and late apoptosis ($p<0.001$ for both comparisons, Figure 5C) which may explain the lack of significantly enhanced MIF production in some of the donors. Taken together, these results show that malarial pigment decreases MIF production from PBMC, independent of altered cell viability or apoptosis.

ACCEPTED

DISCUSSION

A number of studies in murine models of malaria suggest that there is a circulating host-derived inflammatory mediator(s) that inhibits the erythropoietic response (46, 62, 71), and recent evidence has identified MIF as that potential immune mediator that suppresses erythropoiesis during malaria (41, 43). However, the role of MIF in regulating anemia in childhood malaria remains unclear because of contradictory findings in small cohorts of children (7, 43). While our previous study demonstrated suppression of circulating MIF and *ex vivo* PBMC MIF transcripts in Gabonese children with acute malaria versus healthy, a parasitemic controls (7), subsequent investigations illustrated that plasma MIF levels were elevated in Zambian children with malarial anemia relative to healthy controls (43).

To further investigate the role of MIF in the immunopathogenesis of malarial anemia, the relationship between MIF production and anemia was investigated in a large cohort of clinically well-characterized children that were stratified according to the severity of malarial anemia. These studies confirmed our previous finding in Gabon (7) and extended this observation by demonstrating that circulating MIF levels and MIF production from PBMC isolated from children with acute malaria progressively declined with increasing severity of malarial anemia. Results presented here also illustrated that there was a significant positive correlation between circulating MIF levels and Hb concentrations. Moreover, the large sample size in the current study allowed us to confirm the significant positive association between MIF and Hb by conducting multivariate regression analyses that controlled for important confounders such as age. Our previous studies in this cohort of children demonstrated that the reticulocyte response was inappropriate for the level of anemia, and that children with malarial anemia had suppression of erythropoiesis (67). Correlation analyses examining the relationship between MIF and erythropoiesis revealed that MIF was not significantly associated with the absolute reticulocyte number, suggesting that circulating MIF may not be responsible for suppression of erythropoiesis.

The basis of different MIF production patterns in Zambian children (43) versus those in Gabon (7) and in Kenyan children presented here remains to be defined. However, our studies in western Kenya and those of others (2, 10, 29, 53) have shown that children presenting with malarial anemia often have co-infections with bacteremia and HIV-1 which could potentially alter MIF production. Although children with co-infections were excluded from our analyses, it is not certain if such co-infected children were excluded from other studies. In addition, since RBC contain substantial quantities of MIF (47), the use of plasma from hemolyzed blood could yield falsely elevated MIF concentrations. For analysis of circulating MIF in the current study, all plasma samples were examined by an individual who was blinded to the clinical categories of study participants, and those samples with evidence of hemolysis were excluded from measurement. Furthermore, it is well documented that malaria transmission intensity conditions the host immune response and age-specific pathophysiological manifestations of *P. falciparum* (40, 63). The relatively older children examined in Zambia (mean age: 25.5 mos.), where *P. falciparum* endemicity is lower, therefore, may have different immunopathogenic mechanisms responsible for the promotion of malarial anemia than the younger children examined here in western Kenya (see Table 1) residing in a holoendemic transmission area.

Recent investigations illustrated that MIF suppresses erythropoietin-dependent colony formation in cultured erythroid progenitor cells and Hb synthesis in murine and human cell lines (43). Additional studies showed that elevated MIF concentrations are present in bone marrow lysates of *P. chabaudi*-infected mice (41). However, measurement of MIF concentrations in the bone marrow of children with SMA will be important for understanding the role of MIF in human malaria since contrasting roles of MIF in murine studies (41, 43) versus those in human is not unprecedented. For example, previous investigations revealed that MIF production in response to glucocorticoids differs in murine and human systems (3, 30). Furthermore, while anemia in murine models of malaria closely correlate with peripheral parasitemia and RBC hemolysis, data presented here illustrate that parasite density and anemia severity are unrelated in children with

SMA. It is also important to note that MIF production during malaria appears to be both tissue- and compartment-specific (19, 20, 23). For example, previous studies in women with placental malaria showed increased MIF locally in intervillous blood in the presence of decreased peripheral blood MIF concentrations (20). Therefore, our findings do not exclude the possibility that MIF may be increased in the local milieu within the bone marrows of the children in our cohort despite the reduced concentrations of MIF in the peripheral circulation.

Previous studies in malaria-endemic regions illustrate that phagocytosis of *p*fHz by monocytes and neutrophils is a better index of disease severity than peripheral parasitemia (4, 18, 39, 45, 48). This may be related to the fact that concomitant peripheral parasitemia does not account for parasite sequestration within microvascular networks and/or the duration of infection. In this study, there was a lower prevalence of PCM and PCN than previously observed by others (4, 39, 45). This may be because children in the present study were younger and, therefore, likely more immune-naïve to *P. falciparum*. Importantly, the clearance kinetics of PCM and PCN differ considerably, with median PCM and PCN clearance times of approximately ten and four days, respectively (27). Increased abundance of PCM relative to PCN in the current cohort suggests that malarial anemia results from prolonged (chronic) malaria infections. Although Hz has been shown to regulate MIF production *in vitro* (6, 43), the relationship between MIF production and Hz levels *in vivo* has not previously been examined. Multivariate analyses controlling for age, gender, and parasitemia revealed a significant association between increased levels of PCM, SMA, and decreased circulating MIF levels, suggesting that acquisition of *p*fHz by monocytes may promote SMA and suppress peripheral MIF production.

Based on the statistical relationship between elevated PCM and decreased MIF, malarial pigment was investigated as a parasitic source responsible for MIF suppression in children with SMA. A series of experiments in cultured PBMC from malaria-naïve donors identified two main types of responders: those who increased MIF production and those who decreased MIF

production in response to stimulation by physiological doses (33) of *p*fHz or sHz. Cell viability experiments further demonstrated that reductions in MIF production were not mediated by loss in cell viability or increased apoptosis. Identical results observed with *p*fHz and sHz demonstrate that the core ferriprotoporphyrin-IX structure, rather than adherent host and/or parasitic proteins, lipids or nucleic acids is responsible for altering MIF production. Recent studies in cultured mononuclear cells from individuals with low (5-CATT/5-CATT) and high expression MIF-794 alleles (6-CATT/6-CATT and 6-CATT/7-CATT) show that MIF production in response to sHz stimulation was genotype-dependent (43). Although the genetic background of the donors examined in the present study were unknown, subsequent investigations in our laboratories have revealed that PBMC from individuals with the GG genotype at MIF -173 have increased MIF production, while GC individuals have decreased MIF production following stimulation with *p*fHz (6). It is, therefore, not surprising that circulating MIF concentrations were generally inversely correlated with PCM levels in the study cohort, since the C allele is predominant in this cohort of children (6). The molecular mechanism(s) by which acquisition of malarial pigment decreases MIF production remains to be defined. **However, previous studies demonstrated that ingestion of Hz causes impairment of several cellular functions including cytokine secretion, phagocytosis, and antigen-presentation (59, 60). It remains to be determined if suppression of MIF in response to Hz occurs through a direct or indirect mechanism following phagocytosis of Hz.** Taken together, results presented here, which represent the most comprehensive examination to date on the role of MIF in promoting childhood malarial anemia, suggest that MIF may not be responsible for enhanced anemia in pediatric populations with acute falciparum malaria, and that monocytic ingestion of Hz is responsible, either directly or indirectly, for suppression of MIF.

ACKNOWLEDGEMENT

We are very grateful to all the parents, guardians and children from the Siaya District community and the US donors for their participation in this study. We would also like to thank the University of Pittsburgh/KEMRI staff and the Siaya District Hospital staff for their support during the study. We thank the Director of KEMRI for approving this manuscript for publication.

ACCEPTED

REFERENCES

1. Abdalla, S. H. 1990. Hematopoiesis in human malaria. *Blood Cells* 16:401-416; discussion 417-409.
2. Akpede, G. O., and R. M. Sykes. 1993. Malaria with bacteraemia in acutely febrile preschool children without localizing signs: coincidence or association/complication? *J Trop Med Hyg* 96:146-150.
3. Alourfi, Z., R. P. Donn, A. Stevens, A. Berry, A. McMaster, and D. W. Ray. 2005. Glucocorticoids suppress macrophage migration inhibitory factor (MIF) expression in a cell-type-specific manner. *J Mol Endocrinol* 34:583-595.
4. Amodu, O. K., A. A. Adeyemo, P. E. Olumese, and R. A. Gbadegesin. 1998. Intraleucocytic malaria pigment and clinical severity of malaria in children. *Trans R Soc Trop Med Hyg* 92:54-56.
5. Arese, P., and E. Schwarzzer. 1997. Malarial pigment (haemozoin): a very active 'inert' substance. *Ann Trop Med Parasitol* 91:501-516.
6. Awandare, G. A., C. Ouma, C. C. Keller, T. Were, R. Otieno, Y. Ouma, G. C. Davenport, J. B. Hittner, J. M. Ong'echa, R. Ferrell, and D. J. Perkins 2006. A macrophage migration inhibitory factor promoter polymorphism is associated with high-density parasitemia in children with malaria. *Genes Immun*. doi:10.1038/sj.gene.6364332.
7. Awandare, G. A., J. B. Hittner, P. G. Kremsner, D. O. Ochiel, C. C. Keller, J. B. Weinberg, I. A. Clark, and D. J. Perkins. 2006. Decreased circulating macrophage migration inhibitory factor (MIF) protein and blood mononuclear cell MIF transcripts in children with *Plasmodium falciparum* malaria. *Clin Immunol* 119:219-225.
8. Bacher, M., C. N. Metz, T. Calandra, K. Mayer, J. Chesney, M. Lohoff, D. Gemsa, T. Donnelly, and R. Bucala. 1996. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. *Proc Natl Acad Sci U S A* 93:7849-7854.

9. Beier, J. C., C. N. Oster, F. K. Onyango, J. D. Bales, J. A. Sherwood, P. V. Perkins, D. K. Chumo, D. V. Koech, R. E. Whitmire, C. R. Roberts, and et al. 1994. *Plasmodium falciparum* incidence relative to entomologic inoculation rates at a site proposed for testing malaria vaccines in western Kenya. *Am J Trop Med Hyg* 50:529-536.
10. Berkley, J., S. Mwarumba, K. Bramham, B. Lowe, and K. Marsh. 1999. Bacteraemia complicating severe malaria in children. *Trans R Soc Trop Med Hyg* 93:283-286.
11. Bernhagen, J., T. Calandra, R. A. Mitchell, S. B. Martin, K. J. Tracey, W. Voelter, K. R. Manogue, A. Cerami, and R. Bucala. 1993. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. *Nature* 365:756-759.
12. Bozza, M., A. R. Satoskar, G. Lin, B. Lu, A. A. Humbles, C. Gerard, and J. R. David. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. *J Exp Med* 189:341-346.
13. Breman, J. G., A. Egan, and G. T. Keusch. 2001. The intolerable burden of malaria: a new look at the numbers. *Am J Trop Med Hyg* 64:iv-vii.
14. Burchard, G. D., P. Radloff, J. Philipps, M. Nkeyi, J. Knobloch, and P. G. Kremsner. 1995. Increased erythropoietin production in children with severe malarial anemia. *Am J Trop Med Hyg* 53:547-551.
15. Calandra, T., J. Bernhagen, R. A. Mitchell, and R. Bucala. 1994. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. *J Exp Med* 179:1895-1902.
16. Calandra, T., B. Echtenacher, D. L. Roy, J. Pugin, C. N. Metz, L. Hultner, D. Heumann, D. Mannel, R. Bucala, and M. P. Glauser. 2000. Protection from septic shock by neutralization of macrophage migration inhibitory factor. *Nat Med* 6:164-170.
17. Calandra, T., and T. Roger. 2003. Macrophage migration inhibitory factor: a regulator of innate immunity. *Nat Rev Immunol* 3:791-800.

18. Casals-Pascual, C., O. Kai, J. O. Cheung, S. Williams, B. Lowe, M. Nyanoti, T. N. Williams, K. Maitland, M. Molyneux, C. R. Newton, N. Peshu, S. M. Watt, and D. J. Roberts. 2006. Suppression of erythropoiesis in malarial anemia is associated with hemozoin *in vitro* and *in vivo*. *Blood*. DOI 10.1182/blood-2006-05-018697. *in press*
19. Chaisavaneeyakorn, S., N. Lucchi, C. Abramowsky, C. Othoro, S. C. Chaiyaroj, Y. P. Shi, B. L. Nahlen, D. S. Peterson, J. M. Moore, and V. Udhayakumar. 2005. Immunohistological characterization of macrophage migration inhibitory factor expression in *Plasmodium falciparum*-infected placentas. *Infect Immun* 73:3287-3293.
20. Chaisavaneeyakorn, S., J. M. Moore, C. Othoro, J. Otieno, S. C. Chaiyaroj, Y. P. Shi, B. L. Nahlen, A. A. Lal, and V. Udhayakumar. 2002. Immunity to placental malaria. IV. Placental malaria is associated with up-regulation of macrophage migration inhibitory factor in intervillous blood. *J Infect Dis* 186:1371-1375.
21. Chaiyaroj, S. C., A. S. Rutta, K. Muenthaisong, P. Watkins, M. Na Ubol, and S. Looareesuwan. 2004. Reduced levels of transforming growth factor-beta1, interleukin-12 and increased migration inhibitory factor are associated with severe malaria. *Acta Trop* 89:319-327.
22. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162:156-159.
23. Clark, I. A., M. M. Awburn, R. O. Whitten, C. G. Harper, N. G. Liomba, M. E. Molyneux, and T. E. Taylor. 2003. Tissue distribution of migration inhibitory factor and inducible nitric oxide synthase in falciparum malaria and sepsis in African children. *Malar J* 2:6.
24. Clark, I. A., and W. B. Cowden. 2003. The pathophysiology of falciparum malaria. *Pharmacol Ther* 99:221-260.
25. Clark, I. A., J. L. Virelizier, E. A. Carswell, and P. R. Wood. 1981. Possible importance of macrophage-derived mediators in acute malaria. *Infect Immun* 32:1058-1066.

26. David, J. R. 1966. Delayed hypersensitivity *in vitro*: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 56:72-77.
27. Day, N. P., T. D. Pham, T. L. Phan, X. S. Dinh, P. L. Pham, V. C. Ly, T. H. Tran, T. H. Nguyen, D. B. Bethell, H. P. Nguyen, T. H. Tran, and N. J. White. 1996. Clearance kinetics of parasites and pigment-containing leukocytes in severe malaria. Blood 88:4694-4700.
28. Goldie, P., E. F. Roth, Jr., J. Oppenheim, and J. P. Vanderberg. 1990. Biochemical characterization of *Plasmodium falciparum* hemozoin. Am J Trop Med Hyg 43:584-596.
29. Graham, S. M., A. L. Walsh, E. M. Molyneux, A. J. Phiri, and M. E. Molyneux. 2000. Clinical presentation of non-typhoidal Salmonella bacteraemia in Malawian children. Trans R Soc Trop Med Hyg 94:310-314.
30. Isidori, A. M., G. A. Kaltsas, M. Korbonits, M. Pyle, M. Gueorguiev, A. Meinhardt, C. Metz, N. Petrovsky, V. Popovic, R. Bucala, and A. B. Grossman. 2002. Response of serum macrophage migration inhibitory factor levels to stimulation or suppression of the hypothalamo-pituitary-adrenal axis in normal subjects and patients with Cushing's disease. J Clin Endocrinol Metab 87:1834-1840.
31. Juttner, S., J. Bernhagen, C. N. Metz, M. Rollinghoff, R. Bucala, and A. Gessner. 1998. Migration inhibitory factor induces killing of *Leishmania major* by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-alpha. J Immunol 161:2383-2390.
32. Keller, C. C., J. B. Hittner, B. K. Nti, J. B. Weinberg, P. G. Kremsner, and D. J. Perkins. 2004. Reduced peripheral PGE2 biosynthesis in *Plasmodium falciparum* malaria occurs through hemozoin-induced suppression of blood mononuclear cell cyclooxygenase-2 gene expression via an interleukin-10-independent mechanism. Mol Med 10:45-54.
33. Keller, C. C., P. G. Kremsner, J. B. Hittner, M. A. Misukonis, J. B. Weinberg, and D. J. Perkins. 2004. Elevated nitric oxide production in children with malarial anemia:

- hemozoin-induced nitric oxide synthase type 2 transcripts and nitric oxide in blood mononuclear cells. *Infect Immun* 72:4868-4873.
34. Koebernick, H., L. Grode, J. R. David, W. Rohde, M. S. Rolph, H. W. Mittrucker, and S. H. Kaufmann. 2002. Macrophage migration inhibitory factor (MIF) plays a pivotal role in immunity against *Salmonella typhimurium*. *Proc Natl Acad Sci U S A* 99:13681-13686.
 35. Kurtzhals, J. A., V. Adabayeri, B. Q. Goka, B. D. Akanmori, J. O. Oliver-Commey, F. K. Nkrumah, C. Behr, and L. Hviid. 1998. Low plasma concentrations of interleukin 10 in severe malarial anaemia compared with cerebral and uncomplicated malaria. *Lancet* 351:1768-1772.
 36. Kurtzhals, J. A., O. Rodrigues, M. Addae, J. O. Commey, F. K. Nkrumah, and L. Hviid. 1997. Reversible suppression of bone marrow response to erythropoietin in *Plasmodium falciparum* malaria. *Br J Haematol* 97:169-174.
 37. Lackritz, E. M., C. C. Campbell, T. K. Ruebush, 2nd, A. W. Hightower, W. Wakube, R. W. Steketee, and J. B. Were. 1992. Effect of blood transfusion on survival among children in a Kenyan hospital. *Lancet* 340:524-528.
 38. Luty, A. J., D. J. Perkins, B. Lell, R. Schmidt-Ott, L. G. Lehman, D. Luckner, B. Greve, P. Matousek, K. Herbich, D. Schmid, J. B. Weinberg, and P. G. Kremsner. 2000. Low interleukin-12 activity in severe *Plasmodium falciparum* malaria. *Infect Immun* 68:3909-3915.
 39. Lyke, K. E., D. A. Diallo, A. Dicko, A. Kone, D. Coulibaly, A. Guindo, Y. Cissoko, L. Sangare, S. Coulibaly, B. Dakouo, T. E. Taylor, O. K. Doumbo, and C. V. Plowe. 2003. Association of intraleukocytic *Plasmodium falciparum* malaria pigment with disease severity, clinical manifestations, and prognosis in severe malaria. *Am J Trop Med Hyg* 69:253-259.
 40. Marsh, K., and R. W. Snow. 1997. Host-parasite interaction and morbidity in malaria endemic areas. *Philos Trans R Soc Lond B Biol Sci* 352:1385-1394.

41. Martiney, J. A., B. Sherry, C. N. Metz, M. Espinoza, A. S. Ferrer, T. Calandra, H. E. Broxmeyer, and R. Bucala. 2000. Macrophage migration inhibitory factor release by macrophages after ingestion of *Plasmodium chabaudi*-infected erythrocytes: possible role in the pathogenesis of malarial anemia. *Infect Immun* 68:2259-2267.
42. McDevitt, M. A., J. Xie, V. Gordeuk, and R. Bucala. 2004. The anemia of malaria infection: role of inflammatory cytokines. *Curr Hematol Rep* 3:97-106.
43. McDevitt, M. A., J. Xie, G. Shanmugasundaram, J. Griffith, A. Liu, C. McDonald, P. Thuma, V. R. Gordeuk, C. N. Metz, R. Mitchell, J. Keefer, J. David, L. Leng, and R. Bucala. 2006. A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia. *J Exp Med*. 203(5):1185-96
44. McElroy, P. D., F. O. ter Kuile, A. A. Lal, P. B. Bloland, W. A. Hawley, A. J. Oloo, A. S. Monto, S. R. Meshnick, and B. L. Nahlen. 2000. Effect of *Plasmodium falciparum* parasitemia density on hemoglobin concentrations among full-term, normal birth weight children in western Kenya, IV. The Asembo Bay Cohort Project. *Am J Trop Med Hyg* 62:504-512.
45. Metzger, W. G., B. G. Mordmuller, and P. G. Kremsner. 1995. Malaria pigment in leucocytes. *Trans R Soc Trop Med Hyg* 89:637-638.
46. Miller, K. L., J. C. Schooley, K. L. Smith, B. Kullgren, L. J. Mahlmann, and P. H. Silverman. 1989. Inhibition of erythropoiesis by a soluble factor in murine malaria. *Exp Hematol* 17:379-385.
47. Mizue, Y., J. Nishihira, T. Miyazaki, S. Fujiwara, M. Chida, K. Nakamura, K. Kikuchi, and M. Mukai. 2000. Quantitation of macrophage migration inhibitory factor (MIF) using the one-step sandwich enzyme immunosorbent assay: elevated serum MIF concentrations in patients with autoimmune diseases and identification of MIF in erythrocytes. *Int J Mol Med* 5:397-403.

48. Nguyen, P. H., N. Day, T. D. Pram, D. J. Ferguson, and N. J. White. 1995. Intraleucocytic malaria pigment and prognosis in severe malaria. *Trans R Soc Trop Med Hyg* 89:200-204.
49. Nussenblatt, V., G. Mukasa, A. Metzger, G. Ndeezi, E. Garrett, and R. D. Semba. 2001. Anemia and interleukin-10, tumor necrosis factor alpha, and erythropoietin levels among children with acute, uncomplicated *Plasmodium falciparum* malaria. *Clin Diagn Lab Immunol* 8:1164-1170.
50. Ochiel, D. O., G. A. Awandare, C. C. Keller, J. B. Hittner, P. Kremsner, J. B. Weinberg, and D. J. Perkins. 2005. Differential regulation of beta-chemokines in children with acute falciparum malaria. *Infect Immun* 73:4190-4197.
51. Ong'echa, J. M., C. C. Keller, T. Were, C. Ouma, R. O. Otieno, Z. Landis-Lewis, D. Ochiel, J. L. Slingluff, S. Mogere, G. A. Ogonji, A. S. Orago, J. M. Vulule, S. S. Kaplan, R. D. Day, and D. J. Perkins. 2006. Parasitemia, Anemia, and Malarial Anemia in Infants and Young Children in a Rural Holoendemic *Plasmodium falciparum* Transmission Area. *Am J Trop Med Hyg* 74:376-385.
52. Othoro, C., A. A. Lal, B. Nahlen, D. Koech, A. S. Orago, and V. Udhayakumar. 1999. A low interleukin-10 tumor necrosis factor-alpha ratio is associated with malaria anemia in children residing in a holoendemic malaria region in western Kenya. *J Infect Dis* 179:279-282.
53. Otieno, R. O., C. Ouma, J. M. Ong'echa, C. C. Keller, T. Were, E. N. Waindi, M. G. Michaels, R. D. Day, J. M. Vulule, and D. J. Perkins. 2006. Increased severe anemia in HIV-1-exposed and HIV-1-positive infants and children during acute malaria. *Aids* 20:275-280.
54. Perkins, D. J., J. M. Moore, J. Otieno, Y. P. Shi, B. L. Nahlen, V. Udhayakumar, and A. A. Lal. 2003. *In vivo* acquisition of hemozoin by placental blood mononuclear cells suppresses PGE2, TNF-alpha, and IL-10. *Biochem Biophys Res Commun* 311:839-846.

55. Perkins, D. J., J. B. Weinberg, and P. G. Kremsner. 2000. Reduced interleukin-12 and transforming growth factor-beta1 in severe childhood malaria: relationship of cytokine balance with disease severity. *J Infect Dis* 182:988-992.
56. Pichyangkul, S., P. Saengkrai, and H. K. Webster. 1994. *Plasmodium falciparum* pigment induces monocytes to release high levels of tumor necrosis factor-alpha and interleukin-1 beta. *Am J Trop Med Hyg* 51:430-435.
57. Reyes, J. L., L. I. Terrazas, B. Espinoza, D. Cruz-Robles, V. Soto, I. Rivera-Montoya, L. Gomez-Garcia, H. Snider, A. R. Satoskar, and M. Rodriguez-Sosa. 2006. Macrophage migration inhibitory factor contributes to host defense against acute *Trypanosoma cruzi* infection. *Infect Immun* 74:3170-3179.
58. Satoskar, A. R., M. Bozza, M. Rodriguez Sosa, G. Lin, and J. R. David. 2001. Migration-inhibitory factor gene-deficient mice are susceptible to cutaneous *Leishmania major* infection. *Infect Immun* 69:906-911.
59. Schwarzer, E., M. Alessio, D. Ulliers, and P. Arese. 1998. Phagocytosis of the malarial pigment, hemozoin, impairs expression of major histocompatibility complex class II antigen, CD54, and CD11c in human monocytes. *Infect Immun* 66:1601-1606.
60. Schwarzer, E., F. Turrini, D. Ulliers, G. Giribaldi, H. Ginsburg, and P. Arese. 1992. Impairment of macrophage functions after ingestion of *Plasmodium falciparum*-infected erythrocytes or isolated malarial pigment. *J Exp Med* 176:1033-1041.
61. Sherry, B. A., G. Alava, K. J. Tracey, J. Martiney, A. Cerami, and A. F. Slater. 1995. Malaria-specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF, MIP-1 alpha, and MIP-1 beta) *in vitro*, and altered thermoregulation *in vivo*. *J Inflamm* 45:85-96.
62. Silverman, P. H., J. C. Schooley, and L. J. Mahlmann. 1987. Murine malaria decreases hemopoietic stem cells. *Blood* 69:408-413.

63. Snow, R. W., J. A. Omumbo, B. Lowe, C. S. Molyneux, J. O. Obiero, A. Palmer, M. W. Weber, M. Pinder, B. Nahlen, C. Obonyo, C. Newbold, S. Gupta, and K. Marsh. 1997. Relation between severe malaria morbidity in children and level of *Plasmodium falciparum* transmission in Africa. *Lancet* 349:1650-1654.
64. Srichaikul, T., M. Wasanasomsithi, V. Poshyachinda, N. Panikbutr, and T. Rabieb. 1969. Ferrokinetic studies and erythropoiesis in malaria. *Arch Intern Med* 124:623-628.
65. Weatherall, D., and P. Abdalla. 1982. The anaemia of *P. falciparum* malaria. *Br. Med. Bull.* 38:147-151.
66. Weinberg, J. B., J. J. Muscato, and J. E. Niedel. 1981. Monocyte chemotactic peptide receptor. Functional characteristics and ligand-induced regulation. *J Clin Invest* 68:621-630.
67. Were, T., J. B. Hittner, C. Ouma, R. O. Otieno, A. S. S. Orago, J. M. Ong'echa, J. M. Vulule, C. C. Keller, and D. J. Perkins. 2006. Suppression of RANTES in Children with *Plasmodium falciparum* Malaria is Associated with Severe Malarial Anemia and Suppression of Erythropoiesis. *Haematologica. in press.*
68. WHO. 2005. World Malaria Report 2005. World Health Organization/United Nations Children's Fund. 2005: http://www.rollbackmalaria.org/wmr2005/pdf/WMReport_Ir.pdf.
69. Wickramasinghe, S. N., and S. H. Abdalla. 2000. Blood and bone marrow changes in malaria. *Baillieres Best Pract Res Clin Haematol* 13:277-299.
70. Xu, D., S. J. McSorley, L. Tetley, S. Chatfield, G. Dougan, W. L. Chan, A. Satoskar, J. R. David, and F. Y. Liew. 1998. Protective effect on *Leishmania major* infection of migration inhibitory factor, TNF-alpha, and IFN-gamma administered orally via attenuated *Salmonella typhimurium*. *J Immunol* 160:1285-1289.
71. Yap, G. S., and M. M. Stevenson. 1991. Production of soluble inhibitor of erythropoiesis during *Plasmodium chabaudi* AS infection in resistant and susceptible mice. *Ann N Y Acad Sci* 628:279-281.

Table 1 : Clinical, parasitological, and hematological characteristics of study participants.

Characteristic	AC	UM	MIMA	MdMA	SMA	p-value
Number, n	39	26	75	98	119	
Age, mos	9.1 (1.2)	14.0 (1.9)	12.2 (0.8)	11.5 (0.6)	10.2 (0.6)	0.005 ^a
Axillary temperature, °C	36.8 (0.2)	37.6 (0.2)	37.6 (0.1)	37.7 (0.1)	37.6 (0.1)	<0.001 ^a
Parasites/μL	0	84118 (22734)	44168 (6092)	48697 (5925)	74490 (10443)	0.117 ^a
Geomean parasites/μL	0	29689	21020	18623	31458	
HDP, n (%)	0	20 (77)	53 (71)	71 (72)	93 (78)	0.656 ^b
Hemoglobin, g/dL	11.7 (0.1)	11.8 (0.2)	9.2 (0.1)	6.9 (0.1)	4.7 (0.1)	<0.001 ^a
Hematocrit, %	35.2 (0.3)	34.5 (1.1)	28.0 (0.4)	21.7 (0.2)	15.1 (0.3)	<0.001 ^a
RBC, x 10 ⁶ /μL	4.91 (0.08)	4.78 (0.13)	4.15 (0.07)	3.23 (0.06)	2.18 (0.05)	<0.001 ^a
ARN, x 10 ³ /μL	97.5 (18.7)	105.7 (16.5)	110.6 (8.7)	147.3 (11.6)	140.7 (10.4)	<0.001 ^a
PCM, %	-	0.8 (0.8)	3.1 (1.0)	7.6 (1.4)	15.2 (1.6)	<0.001 ^a
PCM/μL	-	0.01 (0.01)	0.04 (0.02)	0.09 (0.02)	0.23 (0.03)	<0.001 ^a

Data are presented as mean (SEM) except where otherwise indicated. Comparisons of parasitemia were among parasitemic groups only.

^aKruskal-Wallis test

^bChi-Square test

AC, aparasitemic controls (*P. falciparum* negative, Hb≥11.0 g/dL); UM, uncomplicated malaria (Hb≥11.0 g/dL); MIMA, mild malarial anemia (8.0≤Hb<11.0 g/dL); MdMA, moderate malarial anemia (6.0≤Hb<8.0 g/dL); SMA, severe malarial anemia (Hb<6.0 g/dL). HDP, high density parasitemia (≥10,000 parasites/μL); RBC, red blood cells; ARN, absolute reticulocyte number; PCM, pigment-containing monocytes.

Table 2: Relationship between monocyte acquisition of hemozoin and disease severity in children with malaria.

Characteristic	Percent pigment-containing monocytes (PCM)			p-value
	No PCM (0%)	Low PCM ($\leq 10\%$)	High PCM ($> 10\%$)	
Number, <i>n</i> (%)	162 (53)	62 (20)	82 (27)	
Age, <i>mos</i>	11.3 (0.5)	12.2 (0.9)	11.1 (0.8)	0.645 ^a
Parasitemia, μL	49371 (5088)	60141 (9906)	80447 (13266) ^b	0.034 ^a
HDP, <i>n</i> (%)	113 (70)	50 (79)	67 (82)	0.086 ^c
Hemoglobin, <i>g/dL</i>	7.8 (0.2)	6.5 (0.2)	5.7 (0.2) ^d	< 0.001 ^a
SMA, <i>n</i> (%)	34 (21)	28 (46)	53 (65) ^d	< 0.001 ^b
Odds of SMA ^e	1	3.4 (1.8-6.6)	7.5 (4.1-14.0)	

Data are presented as mean (SEM) unless otherwise indicated.

^aKruskal-Wallis test

^bSignificantly different from *no* PCM group, but not *low* PCM group

^cChi-Square test

^dSignificantly different from *No PCM* and *low PCM* groups.

^eMultivariate logistic regression using *No PCM* group as reference and controlling for age, gender, and parasitemia; shown as odds ratio (95% confidence interval), $p < 0.0001$ for both *low* and *high* PCM groups.

HDP, high density parasitemia ($\geq 10,000$ parasites/ μL); SMA, severe malarial anemia (Hb < 6.0 g/dL).

FIGURE LEGENDS

Figure 1. Relationship of plasma MIF with anemia, parasite density and absolute reticulocyte number. Plasma levels of MIF in children with malaria and controls were determined by ELISA. **(A)** Data are presented according to anemia categories: uncomplicated malaria (UM, $Hb \geq 11.0$ g/dL, $n=23$), mild malarial anemia (MIMA, $8.0 \leq Hb < 11.0$ g/dL, $n=71$), moderate MA (MdMA, $6.0 \leq Hb < 8.0$ g/dL, $n=94$) and severe MA (SMA, $Hb < 6.0$ g/dL, $n=109$). Aparasitemic controls (AC, $n=39$) with $Hb \geq 11.0$ g/dL were used as a reference group. Boxes represent the interquartile range, the line through the box is the median, whiskers show 10th and 90th percentiles, and symbols are outliers. Median (interquartile range) levels of MIF were: AC, 4383 (2807-6376); UM, 5225 (3615-9071); MIMA, 4611 (3270-6665); MdMA, 4197 (2862-5743); and SMA, 3422 (1566-4993). * $p < 0.05$, ** $p < 0.001$; Mann-Whitney U tests conducted after analysis of variance (Kruskal-Wallis test) revealed significant differences across groups. Linear relationships of plasma MIF levels with hemoglobin concentrations **(B)**, parasite density **(C)**, and absolute reticulocyte number (ARN) **(D)**, in children with malaria ($n=298$) are shown as scatter plots. MIF concentrations and parasitemia were log-transformed, while the ARN was square root (sqrt)-transformed for normality. Statistical associations were determined by Pearson's correlation tests.

Figure 2. Correlation of peripheral blood leukocytes (PBL) MIF mRNA with circulating MIF. Levels of MIF mRNA in PBL ($n=13$) were determined by real time RT-PCR and expressed relative to endogenous β -actin mRNA levels. The scatter plot shows the correlation of PBL MIF mRNA with circulating MIF levels in matched samples. Statistical association was determined by Pearson's rank correlation test.

Figure 3. MIF production from peripheral blood mononuclear cells (PBMC) of children with acute malaria. Peripheral blood mononuclear cells (PBMC) were isolated from children

with acute malaria and healthy controls (AC) and cultured for 48 hrs: AC (n=24), UM (n=15), MIMA (n=37), MdMA (n=13), and SMA (n=5). MIF concentrations in culture supernatants were determined by ELISA and presented as box plots in which the box represents the interquartile range, the line through the box is the median, whiskers show 10th and 90th percentiles, and symbols are outliers. Median (interquartile range) levels of MIF were: AC, 1034 (615-1902); UM, 2218 (1418-3989); MIMA, 1609 (940-2439); MdMA, 842 (495-3737); and SMA, 511 (264-2312) pg/mL. * $p < 0.05$, ** $p < 0.005$, Mann-Whitney U tests conducted after analysis of variance (Kruskal-Wallis test) revealed significant differences between the groups.

Figure 4. Relationship between plasma MIF levels and pigment-containing monocytes.

Giemsa-stained blood smears obtained from children with malaria were examined for the presence of pigment-containing monocytes (PCM). **(A)** Plasma levels of MIF are presented according to percentage of total monocytes containing pigment: *No PCM* (no PCM observed, n=149), *low PCM* ($\leq 10\%$ PCM, n=60) and *high PCM* ($> 10\%$ PCM, n=79). Boxes represent the interquartile range, the line through the box is the median, whiskers show 10th and 90th percentiles, and symbols are outliers. Median (interquartile range) levels of MIF were: *No PCM*, 4417 (3112-6266); *low PCM*, 4584 (2019-6331); and *high PCM*, 4417 (3112-6266). * $p < 0.05$, ** $p < 0.005$; Mann-Whitney U tests conducted after analysis of variance (Kruskal-Wallis test) revealed significant differences across groups. **(B)** Correlation between circulating MIF concentrations and PCM/ μ L of blood. MIF levels were log-transformed while PCM/ μ L values were square-root-transformed for normality and Pearson's correlation test was used to examine statistical association.

Figure 5. Effects of hemozoin on MIF production and apoptosis of cultured leukocytes.


PBMC from malaria-naïve donors were cultured (1×10^6 cells/mL) in the presence of media alone (Con), 10 μ g/mL hemozoin (*p*Hz), 10 μ g/mL β -hematin (*s*Hz), or a combination of 100 ng/mL

lipopolysaccharide (L) and 200 U/mL IFN- γ (I). **(A)**. Supernatants were harvested after 48 hrs of incubation and MIF concentrations determined by ELISA. Data shown are for three donors representative of individuals for whom MIF increased (Group 1) and three donors representative of individuals for whom MIF decreased (Group 2) in response to stimulation with $p\mu$ Hz and sHz. Differences in MIF levels between treated cells and control conditions were statistically significant ($p < 0.05$ for all comparisons, Student's t test). **(B)**. Cell viability was assessed in PBMC of 3 donors after 48 hrs of culture using a methylthiazole tetrazolium (MTT) assay, and expressed as percent control. **(C)**. PBMC apoptosis was determined by detecting nucleosomes in cell lysates and supernatants at 48 hrs using ELISA. Data are presented as mean (SEM) of independent experiments. * $P < 0.05$ compared to Con; Student's t test.

ACCEPTED

Figure 1

A.



B.





Figure 1 continued

C.



D.






Figure 2



ACCEPTED


Figure 3



ACCEPTED

Figure 4

A.



B.





Figure 5

A.



B.




Figure 5 continued

C.

